Tag archive for ‘Inhibitex’
Will Inhibitex Be The Next Big Acquisition in the HCV Space ? (INHX, $10.69)
Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday’s close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]